Last Price$155.9(0.3%)
Market Cap$19.3B
LTM Research & Development Expenses (R&D)
$127.0M
YoY Growth
-5.2%
3Y CAGR
-4.1%
5Y CAGR
-1.4%
Stock quality & Intrinsic value
7/10
24.8% overvalued
The Clorox Company Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $88.0M | $99.0M | $108.0M | $111.0M | $114.0M | $119.0M | $115.0M | $121.0M | $130.0M | $125.0M | $136.0M | $141.0M | $135.0M | $132.0M | $136.0M | $145.0M | $149.0M | $132.0M | $138.0M | $126.0M |
Overvalued or undervalued?
Check the intrinsic value for CLX
and see if it's the right time to invest.
The Clorox Company (CLX) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
The Clorox CompanyCLX
$127.0M
(5.2%)
(4.1%)
(1.4%)
Median Peer Set
$71.0M
(22.2%)
0.0%
0.0%
Unilever PLCUL
$1,026.6M
(44.5%)
(19.2%)
(13.8%)
The Estée Lauder Companies Inc.EL
$360.0M
4.7%
N/A
12.3%
Kenvue Inc.KVUE
$205.0M
(48.6%)
26.2%
N/A
Coty Inc.COTY
$126.8M
20.5%
9.5%
N/A
Hims & Hers Health, Inc.HIMS
$78.8M
63.4%
88.3%
N/A
Church & Dwight Co., Inc.CHD
$63.1M
(48.4%)
(15.7%)
(7.6%)
e.l.f. Beauty, Inc.ELF
$0.0
N/A
N/A
N/A
Colgate-Palmolive CompanyCL
$0.0
(100.0%)
(100.0%)
(100.0%)
Kimberly-Clark CorporationKMB
$0.0
(100.0%)
(100.0%)
(100.0%)
The Procter & Gamble CompanyPG
$0.0
N/A
N/A
N/A
CLX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jun'05 | Jun'06 | Jun'07 | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Jun'16 | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 4,388.0 1.5% | 4,644.0 5.8% | 4,847.0 4.4% | 5,273.0 8.8% | 5,450.0 3.4% | 5,534.0 1.5% | 5,231.0 (5.5%) | 5,468.0 4.5% | 5,623.0 2.8% | 5,591.0 (0.6%) | 5,655.0 1.1% | 5,761.0 1.9% | 5,973.0 3.7% | 6,124.0 2.5% | 6,214.0 1.5% | 6,721.0 8.2% | 7,341.0 9.2% | 7,107.0 (3.2%) | 7,389.0 4.0% | 7,093.0 (4.0%) |
| Cost of Goods Sold (COGS) | 2,493.0 | 2,685.0 | 2,756.0 | 3,098.0 | 3,104.0 | 3,057.0 | 2,958.0 | 3,164.0 | 3,211.0 | 3,231.0 | 3,190.0 | 3,163.0 | 3,302.0 | 3,449.0 | 3,486.0 | 3,658.0 | 4,142.0 | 4,562.0 | 4,481.0 | 4,045.0 |
% margin | 1,895.0 43.2% | 1,959.0 42.2% | 2,091.0 43.1% | 2,175.0 41.2% | 2,346.0 43.0% | 2,477.0 44.8% | 2,273.0 43.5% | 2,304.0 42.1% | 2,412.0 42.9% | 2,360.0 42.2% | 2,465.0 43.6% | 2,598.0 45.1% | 2,671.0 44.7% | 2,675.0 43.7% | 2,728.0 43.9% | 3,063.0 45.6% | 3,199.0 43.6% | 2,545.0 35.8% | 2,908.0 39.4% | 3,048.0 43.0% |
| Operating Expenses | 1,078.0 | 1,180.0 | 1,224.0 | 1,287.0 | 1,328.0 | 1,409.0 | 1,352.0 | 1,401.0 | 1,437.0 | 1,394.0 | 1,457.0 | 1,534.0 | 1,544.0 | 1,539.0 | 1,604.0 | 1,789.0 | 1,943.0 | 1,795.0 | 2,055.0 | 3,048.0 |
| Research & Development Expenses (R&D) | 88.0 | 99.0 | 108.0 | 111.0 | 114.0 | 119.0 | 115.0 | 121.0 | 130.0 | 125.0 | 136.0 | 141.0 | 135.0 | 132.0 | 136.0 | 145.0 | 149.0 | 132.0 | 138.0 | 126.0 |
| Selling, General & Administrative Expenses (SG&A) | 986.0 | 1,081.0 | 1,116.0 | 1,176.0 | 1,214.0 | 1,265.0 | 1,237.0 | 1,280.0 | 1,307.0 | 1,269.0 | 1,321.0 | 1,393.0 | 1,409.0 | 1,407.0 | 1,468.0 | 1,644.0 | 1,794.0 | 1,663.0 | 1,917.0 | 1,999.0 |
% margin | 817.0 18.6% | 779.0 16.8% | 867.0 17.9% | 888.0 16.8% | 1,018.0 18.7% | 1,093.0 19.8% | 921.0 17.6% | 903.0 16.5% | 969.0 17.2% | 959.0 17.2% | 1,001.0 17.7% | 1,056.0 18.3% | 1,117.0 18.7% | 1,125.0 18.4% | 941.0 15.1% | 1,104.0 16.4% | 1,117.0 15.2% | 489.0 6.9% | 1,224.0 16.6% | 916.0 12.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 12.0 | 4.0 | 0.0 | 3.0 | 3.0 | 3.0 | 3.0 | 4.0 | 5.0 | 4.0 | 6.0 | 3.0 | 2.0 | 5.0 | 5.0 | 16.0 | 23.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 168.0 | 161.0 | 139.0 | 123.0 | 125.0 | 122.0 | 103.0 | 100.0 | 88.0 | 88.0 | 85.0 | 97.0 | 99.0 | 99.0 | 106.0 | 90.0 | 90.0 |
| Pre-tax Income | 729.0 | 653.0 | 743.0 | 693.0 | 811.0 | 925.0 | 563.0 | 791.0 | 853.0 | 861.0 | 921.0 | 983.0 | 1,033.0 | 1,054.0 | 1,024.0 | 1,185.0 | 900.0 | 607.0 | 238.0 | 398.0 |
% effective tax rate | 214.0 29.4% | 210.0 32.2% | 247.0 33.2% | 232.0 33.5% | 274.0 33.8% | 322.0 34.8% | 276.0 49.0% | 248.0 31.4% | 279.0 32.7% | 299.0 34.7% | 315.0 34.2% | 335.0 34.1% | 330.0 31.9% | 231.0 21.9% | 204.0 19.9% | 246.0 20.8% | 181.0 20.1% | 136.0 22.4% | 77.0 32.4% | 106.0 26.6% |
% margin | 1,096.0 25.0% | 444.0 9.6% | 501.0 10.3% | 461.0 8.7% | 537.0 9.9% | 603.0 10.9% | 557.0 10.6% | 541.0 9.9% | 572.0 10.2% | 558.0 10.0% | 580.0 10.3% | 648.0 11.2% | 701.0 11.7% | 823.0 13.4% | 820.0 13.2% | 939.0 14.0% | 710.0 9.7% | 462.0 6.5% | 149.0 2.0% | 280.0 3.9% |
| EPS | 6.20 | 2.95 | 3.31 | 3.30 | 3.86 | 4.28 | 4.06 | 4.14 | 4.37 | 4.31 | 4.45 | 5.01 | 5.43 | 6.37 | 6.42 | 7.46 | 5.65 | 3.75 | 1.21 | 2.25 |
| Diluted EPS | 6.11 | 2.90 | 3.26 | 3.24 | 3.81 | 4.24 | 4.02 | 4.09 | 4.30 | 4.23 | 4.37 | 4.92 | 5.33 | 6.25 | 6.32 | 7.35 | 5.58 | 3.73 | 1.20 | 2.24 |
% margin | 982.0 22.4% | 967.0 20.8% | 1,059.0 21.8% | 1,054.0 20.0% | 1,152.0 21.1% | 1,127.0 20.4% | 848.0 16.2% | 1,094.0 20.0% | 1,143.0 20.3% | 1,164.0 20.8% | 1,185.0 21.0% | 1,236.0 21.5% | 1,278.0 21.4% | 1,280.0 20.9% | 1,297.0 20.9% | 1,457.0 21.7% | 1,203.0 16.4% | 928.0 13.1% | 577.0 7.8% | 736.0 10.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is The Clorox Company's Research & Development Expenses (R&D)?
As of today, The Clorox Company's last 12-month Research & Development Expenses (R&D) is $127.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is The Clorox Company's Research & Development Expenses (R&D) growth rate?
Over the last year, The Clorox Company's Research & Development Expenses (R&D) growth was (5.2%). The average annual Research & Development Expenses (R&D) growth rates for The Clorox Company have been (5.2%) over the past three years, (1.4%) over the past five years.
3) Is The Clorox Company's Research & Development Expenses (R&D) growth rate Good?
Over the last year, The Clorox Company's Research & Development Expenses (R&D) growth was (5.2%), which is lower than industry growth of (0.9%). It indicates that The Clorox Company's Research & Development Expenses (R&D) growth is Good.